Introduction
The unique mechanism of action of paclitaxel (taxol) to stabilize microtubules was discovered over 20 years ago [1] . Paclitaxel is the prototype of the taxane family of antitumor drugs and its mechanisms of action along with several other microtubule binding agents are becoming better understood [2] [3] [4] [5] [6] . However, owing to the high tubulin content of neuronal tissues, all tubulin-binding agents tested clinically to date share a common side effect of neurotoxicity. Thus, there have been major efforts to identify or develop novel tubulin-binding drugs with improved toxicity profiles, as these agents have proven to be important drugs in the treatment of a wide variety of cancer types [6] .
Noscapine, a member of the benzylisoquinoline class of alkaloids, is a microtubule stabilizing agent with several promising anticancer properties [7] [8] [9] [10] . It has been widely used as a cough suppressant in Europe and Asia for decades with no evidence of toxicity in humans [8, 11, 12] . More recently, noscapine was shown to reduce mortality rate in stroke victims, again without toxic side effects [9] . It has pleiotropic effects in vitro associated with its ability to induce growth arrest, to induce apoptosis, and to inhibit angiogenic activity PTEN status was wild type in LN229 and mutant in U87MG, U118MG, and T98G [27] . Cell lines were cultured in 5% CO 2 and 95% humidified atmosphere at 371C in Dulbecco's modified Eagle's medium (Gibco BRL, Grand Island, New York, USA) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, California, USA), 1% penicillin and streptomycin, and 2 mmol/l glutamine (Gibco BRL). Cells were split every 3 days to ensure logarithmic growth. All drugs and saponin were purchased from Sigma-Aldrich (St Louis, Missouri, USA). Noscapine hydrochloride (100 mmol/l) and staurosporine (STS) (1 mmol/l) were dissolved in dimethylsulfoxide and stock solutions were stored at -801C. MitoTracker Orange CMTMRos was obtained from Molecular Probes (Eugene, Oregon, USA).
Cytotoxicity studies
For the time course experiments, glioma cells (5 Â 10 5 ) were plated in 10-cm Nunc dishes (Naperville, Illinois, USA) in 10 ml of medium for 24 h at 371C before the addition of noscapine (20-150 mmol/l). Adherent and nonadherent cells (total cells) were harvested at the appropriate time interval and assessed for cell viability by trypan blue dye exclusion assay in triplicate. The IC 50 values were the drug concentrations needed to inhibit glioma cell proliferation by 50% at 24 h of drug exposure.
Cell cycle analysis
For cell cycle analysis, total cells were harvested from each culture condition at the appropriate time interval, washed in ice-cold phosphate-buffered saline (PBS), resuspended in 400 ml of ice-cold PBS, and diluted by drop-wise addition of 1 ml of 100% ethanol. After fixation of > 1 h at 41C, cells were resuspended in RNase A/propidium iodide (PI) mixture containing 0.5 mg/ml RNase A and 50 mg/ml PI in PBS. DNA content was used to distinguish each cell cycle phase using flow cytometry. Flow cytometry was performed on a Becton Dickinson FACSCalibur (San Jose, California, USA).
Detection of mitotic cells by flow cytometry
Total cells were harvested and fixed in ethanol as described above. Following fixation overnight at 41C, cells were washed twice with 1% FBS/PBST (PBS with 0.1% Tween-20), and incubated in anti-MPM-2 monoclonal antibody (1 mg/ml) or anti-phospho-histone H3 rabbit polyclonal antibody (5 mg/ml) (Upstate Biotechnology, Lake Placid, New York, USA) for 1 h at room temperature. Cells were washed twice in 1% FBS/PBST and incubated in fluorescein isothiocyanate (FITC)conjugated donkey antimouse antibody (1 : 300; Jackson ImmunoResearch Laboratories, Inc., West Grove, Pennsylvania, USA) for 1 h at room temperature. Cells were washed twice in PBS and resuspended in 50 mg/ml PI containing 0.5 mg/ml RNase A in PBS. Cells were analyzed on a Becton Dickinson FACSCalibur for cell cycle distribution and mitotic index (percentage of MPM-2-positive or phospho-histone H3 (p-H3)-positive cells containing 4N DNA content). Dot plots and histograms of the MPM-2 or PI signal were obtained using the CellQuest software (BD Biosciences, San Jose, California, USA).
Western blot analysis
Total cells were harvested from each culture condition at the appropriate time interval, washed with ice-cold PBS, and lysed in a buffer containing Triton X-100 and Nonidet P-40 supplemented with protease inhibitors. Quantitation of protein was carried out with the BCA reagent (Pierce, Rockford, Illinois, USA). Equal amounts of protein (30 mg) in the presence of 5% b-mercaptoethanol (Sigma-Aldrich) were electrophoresed on 7.5% [b-actin, cyclin B1, MPM-2, poly (ADP-ribose) polymerase (PARP)] or 12% [apoptosis-inducing factor (AIF), Bcl-2, cytochrome c, phospho-Cdc2, extracellular signal regulated kinase (ERK), phospho-ERK, p-H3, phosphoc-Jun, c-Jun, survivin] sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels. Proteins were transferred to Immobilon-P membranes (Millipore, Bedford, Massachusetts, USA) by electroblotting at 30 V overnight at 41C. Membranes were blocked for 1 h with 5% nonfat milk in PBST. Immunoblotting was performed at 41C overnight with the following antibodies: mouse antiactin monoclonal antibody used at 1 : 20 000 (clone C4; Chemicon International, Inc., Temecula, California, USA); mouse anti-Bcl-2 monoclonal antibody used at 1 : 2000 (clone 124; Dako, North America, Inc., Carpenteria, California, USA); rabbit anti-Bax polyclonal antibody used at 1 : 1000 (Cell Signaling Technology, Danvers, Massachusetts, USA); mouse anti-PARP monoclonal antibody used at 1 : 500 (Ab-2, Oncogene, San Diego, California, USA); rabbit antisurvivin polyclonal antibody used at 1 : 1000 (Novus Biologicals Inc., Littleton, Colorado, USA); mouse anticyclin B1 monoclonal antibody used at 1 : 1000 (Santa Cruz Biotechnology, Santa Cruz, California, USA); mouse anti-MPM-2 monoclonal antibody used at 1 : 2000 (Upstate Biotechnology); and rabbit anti-phospho-histone H3 (Ser 10 ) polyclonal antibody used at 1 : 1000 (Upstate Biotechnology); mouse anticytochrome c monoclonal antibody used at 1 : 1000 (BD Biosciences, San Jose, California, USA); rabbit anti-AIF polyclonal antibody used at 1 : 500 (Santa Cruz Biotechnology); rabbit anti-ERK1/2 polyclonal antibody used at 1 : 1000 (Cell Signaling Technology); mouse anti-phospho-ERK1/2 (Tyr 204 ) monoclonal antibody used at 1 : 500 (clone E-4; Santa Cruz Biotechnology); rabbit anti-phospho-Cdc2 (Tyr 15 ) polyclonal antibody used at 1 : 1000 (Cell Signaling Technology); rabbit anti-phospho-c-Jun (Ser 63 ) polyclonal antibody used at 1 : 1000; and rabbit anti-c-Jun monoclonal antibody used at 1 : 500 (Cell Signaling Technology). Sheep antimouse IgG and donkey antirabbit IgG (both from GE Healthcare, Buckingamshire, UK) horseradish peroxidaseconjugated secondary antibodies were used at 1 : 2000.
Immunodetection was carried out with the Supersignal West Femto or West Pico (for b-actin) Maximum Sensitivity Substrate detection system (Pierce) followed by densitometry using NIH Image software.
Cellular fractionation
Total cells were harvested, counted, and washed with PBS. Cells (1 Â 10 6 ) were pelleted for 5 min at 800g and the cell pellet was lysed in 50 ml lysis buffer (80 mmol/l KCl, 250 mmol/l sucrose, 500 mg/ml digitonin, and protease inhibitors) and incubated for 10 min on ice. Cell lysates were centrifuged for 10 min at 10 000g at room temperature and samples were stored at -201C. Proteins from the supernatant (cytosolic fraction) were analyzed by western blotting for cytochrome c and AIF.
Immunofluorescence microscopy for apoptosis-inducing factor, and cytochome c Cells (3 Â10 4 ) were plated on poly-D-lysine-coated (0.1 mg/ml; Sigma-Aldrich) coverslips in 6-well plates and allowed to attach at 371C for 24 h before the addition of the drug. To analyze the release of mitochondrial proteins (AIF, cytochrome c), the cells were untreated or treated with noscapine (100 mmol/l), fixed in 4% paraformaldehyde, permeabilized for 1 min in PBS/0.1% Triton X-100, and nonspecific binding sites were blocked with 2% FBS for 5 min. Cells were incubated with rabbit anti-AIF polyclonal antibody (1 : 100; Santa Cruz Biotechnology) or mouse anticytochrome c monoclonal antibody diluted 1 : 100 (BD Pharmingen, Inc., San Diego, California, USA) overnight at 41C. The secondary FITC-conjugated antibodies were used in accordance with the manufacturer's instructions. Cells were washed twice with PBS and counterstained with PI (20 mg/ml) for 15 min at room temperature. Cells were washed three times with PBS and mounted onto Colorfrost Plus slides (Fisher Scientific, Pittsburgh, Pennsylvania, USA) using VectaShield Hardset (Vector Laboratories, Burlingame, California, USA). Images were captured on a Nikon Eclipse inverted fluorescence microscope with Spot digital camera and processed using Adobe Photoshop 9.0 software.
Detection of apoptosis-inducing factor by flow cytometry
Total cells were incubated for 30 min in media containing 0.1 mmol/l MitoTracker Orange CMTMRos (Molecular Probes, Eugene, Oregon, USA) at 371C and then untreated or treated with noscapine (100 mmol/l). At the appropriate time interval, cells were harvested, fixed in 0.25% paraformaldehyde, and permeabilized for 5 min in PBS/0.01% saponin. Cells were incubated with primary rabbit anti-AIF polyclonal antibody (1 : 100; Santa Cruz Biotechnology) and diluted in PBS/0.01% saponin for 30 min at 41C. Cells were washed and incubated with secondary FITC-conjugated goat antirabbit antibody (1 : 200; Jackson ImmunoResearch Laboratories, Inc.) for 30 min at 41C. Nuclei were stained with Hoechst 33 342 (20 mg/ml; Sigma-Aldrich) for 3 min. The translocation of AIF from the mitochondria to nuclei was analyzed by flow cytometry (LSRII; Becton Dickinson) as described [28] .
Transfection of U87MG glioma cells with small interfering RNA targeting apoptosis-inducing factor expression U87MG cells were plated (3 Â 10 5 ) in 60-mm dishes and after 24 h were transfected. Before transfection the medium was aspirated and 4.6 ml of serum-free medium was added to each plate. Knock-down of AIF expression was performed using validated target sequences (SI02662653; Qiagen, Valencia, California, USA). For transfection, 5 nmol annealed small interfering RNA (siRNA) targeting AIF or the AllStars negative control siRNA [a scrambled (Scr) sequence with no significant homology to any known gene sequences from mouse, rat, or human cell lines] was used. The siRNA sequences were diluted in serum-free medium, mixed with 4 ml Hiperfect (Qiagen), and incubated at room temperature for 10 min. The mixtures were added dropwise to each dish, mixed by gently swirling the dish, and incubated for 4 h at 371C when 0.5 ml of FBS was added for a final concentration of 10%. After incubation at 371C for 48 h, cultures were untreated or treated with noscapine (100 mmol/l) for 16 h. Cells were harvested for trypan blue exclusion assay and western blotting. Two independent experiments were performed. In a separate experiment, cells (1Â10 5 ) were plated onto poly-D-lysinecoated coverslips in 6-well plates, transfected with the appropriate siRNAs, and processed for AIF immunofluorescence microscopy as described above.
Results

Noscapine inhibits cell proliferation
Treatment of U87MG, U118MG, LN229, and T98G glioma cell lines for 72 h with noscapine (20-150 mmol/l) resulted in a dose-dependent inhibition of cell proliferation. Data from three independent studies are summarized in Fig. 1 . When glioma cell lines were treated with noscapine, cell proliferation was inhibited within 24 h of drug exposure. The IC 50 values were 131 mmol/l for U87MG, 91 mmol/l for U118MG, 86 mmol/l for LN229, and 97 mmol/l for T98G. Given the response of the different cell lines to noscapine treatment, we chose the concentration of 100 mmol/l for all further experiments.
Noscapine induces M-phase arrest
Flow cytometry was used to determine DNA content and cell cycle phase ( Fig. 2a ), and expression of the mitosisspecific marker MPM-2 ( Fig. 2b ). Expression of both MPM-2 and p-H3 was analyzed by western blot analysis. Representative data for each of the four cell lines treated with noscapine for 24 h is shown from one of three independent experiments. All the cell lines demonstrated growth arrest at G 2 /M within 24 h of noscapine treatment. Maximal cell death occurred within 48 h of drug exposure (data not shown).
As conventional flow cytometry does not distinguish between cells in G 2 -phase of the cell cycle from those that are in M-phase, we analyzed the expression of the mitosis-specific markers MPM-2 and p-H3 [29, 30] by flow cytometry (Fig. 2b ) and by western blot analysis ( Fig. 2c ). Representative two-dimensional scatter plots of cells double positive for MPM-2 and 4N DNA content (PI staining) showed that the percentage of MPM-2 positive cells increased from a low background level of 2-4% in untreated cultures to 15-60% with noscapine treatment. Similar results were obtained when cells were immunostained with p-H3 and analyzed by flow cytometry (data not shown). Western blot analysis confirmed increased expression of both the MPM-2 and p-H3 mitosis-specific proteins at 24 h in noscapine-treated glioma cells compared with untreated cultures indicating M-phase arrest.
Noscapine alters expression of apoptosis and cell cycle-related proteins
As noscapine treatment induced M-phase arrest, we assessed changes in the expression patterns of several proteins involved in regulating apoptosis and the cell cycle, such as Bcl-2, Bax, cyclin B1, Cdc2, and survivin. Representative data from one of three independent experiments is shown in Fig. 3 . Phosphorylation of Bcl-2 is induced by microtubule binding agents, including one recent report using noscapine [2, 3, 14, 31, 32] . Noscapine treatment of the glioma cell lines for 24 h induced phosphorylation of Bcl-2. The appearance of slower migrating forms of Bcl-2 on western blotting is consistent with its phosphorylation. The U118MG and LN229 cell lines showed two slower migrating bands, compared with only one in U87MG and T98G cell lines (Fig. 3) . The presence of multiple phosphorylated forms of Bcl-2 have been noted previously by others in cells treated with microtubule binding agents [33, 34] . In contrast, the levels of Bax remained unaltered.
Next, we evaluated the expression levels of the cell cycle proteins cyclin B1, Cdc2, and survivin. Representative data for changes in these proteins in glioma cell lines following 24 h of noscapine treatment are shown ( Fig. 3) . Cyclin B1 forms a complex with the Cdc2 kinase to regulate the entry of cells into G 2 /M phase. Activation of Cdc2 kinase is associated with an increased expression of cyclin B1 resulting in cell cycle arrest at G 2 /M phase [35] . Consistent with noscapine-induced M-phase arrest, the Sub level of expression of cyclin B1 was increased. Activation of the mitotic spindle assembly checkpoint is associated with increased levels of phosphorylated histone H3 and reduced phosphorylation of Cdc2 on Tyr 15 , an inhibitory phosphorylation site. Noscapine-treated cells showed a marked decrease in phospho-Cdc2 compared with untreated cells (Fig. 3 ) which is consistent with the upregulation of phospho-H3 ( Fig. 2c ) and increased Cdc2 kinase activity.
Survivin, a member of the chromosomal passenger complex that regulates cell division, is expressed in the G 2 /M phase of the cell cycle and localizes to several sites on the mitotic apparatus, including centrosomes and microtubules in cells in M-phase [36] . When glioma cells were treated with noscapine, survivin levels increased greatly (Fig. 3) . These results, taken together, indicate that changes in expression levels of cell cycle proteins that play important roles in regulating mitosis and the mitotic checkpoint are correlated with noscapine's ability to arrest cells in M-phase. In contrast to noscapine-induced activation of the JNK signaling pathway, the ERK MAPK signaling pathway was inactivated. Both phospho-ERK1/2 bands in noscapinetreated cells were markedly decreased compared with untreated cultures. Although activation of JNK is commonly observed in cells treated with microtubule binding agents, regardless of the interfering mechanism (stabilization vs. destabilization of microtubules), the reported effects of microtubule binding agents on ERK1/2 activity have varied from no effect, to inactivation, or activation [40] [41] [42] . The results reported here suggest that apoptosis induced by noscapine in glioma cells is correlated with activation of the JNK signaling pathway together with the inactivation of the ERK signaling pathway. 
Noscapine induces apoptosis associated with release of mitochondrial proteins cytochrome c and apoptosis-inducing factor
To further explore the mechanism of noscapine-induced apoptosis, we determined whether mitochondrial injury occurred with the release of the mitochondrial proteins cytochrome c and/or AIF release. The results of representative western blots for PARP cleavage (Fig. 5a ), cytochrome c, and AIF release (Fig. 5b ) are shown from one of four independent experiments. The LN229 and T98G cell lines demonstrated the signature cleavage products for PARP (85 kDa) after 24 h of noscapine treatment that were undetectable in the U87MG and U118MG drug-treated cultures. Prolonged exposure to noscapine for up to 72 h in both U87MG and U118MG cell lines did not induce PARP cleavage (data not shown). In contrast, when the same four cell lines were treated for 24 h with staurosporine (1 mmol/l), a broad spectrum kinase inhibitor known to induce apoptosis, PARP cleavage was readily demonstrated (Fig. 5a ). Cellular fractionation studies confirmed release of cytochrome c in only those cell lines that demonstrated PARP cleavage, whereas all cell lines showed increased levels of AIF released into the cytosol following noscapine treatment (Fig. 5b) . Pretreatment of U87MG and U118MG glioma cell lines with the broad spectrum pan caspase inhibitor zVAD-fmk before noscapine treatment failed to block cell death (data not shown). This result is consistent with AIF-dependent apoptosis in the glioma cell lines.
To confirm release of cytochrome c or AIF from the mitochondria, we performed immunofluorescence microscopy and flow cytometry on all cell lines. The representative results are shown for T98G and U87MG cell lines (Fig. 6 ). By immunohistochemistry, no release of cytochrome c was detectable in U87MG cells, where the mitochondria retained a punctate staining pattern (Fig. 6d ) compared with T98G cells that showed a diffuse staining pattern in the cytosol (Fig. 6c) . In contrast, noscapine treatment induced release of AIF from the mitochondria and translocation to the nucleus in both T98G and U87MG cells ( Fig. 6g and h) . Flow cytometry showed approximately a two-fold increase in AIF translocation to the nucleus in both cell lines ( Fig. 6i and j) .
Noscapine induces apoptosis-inducing factor-dependent cell death
To determine whether AIF played a role in noscapineinduced cell death, we performed knock-down of AIF expression in U87MG cells. The results of a representative western blot for AIF expression from one of two independent experiments ( Fig. 7a ) and cell viability (Fig. 7b ) are shown. The experiment was repeated and the cells were processed for AIF immunofluorescence microscopy (Fig. 7c ). AIF expression was decreased in cells transfected with siRNA directed to AIF compared with cells transfected with Scr siRNA. The knockdown of AIF was correlated with decreased cell death in noscapine-treated cultures (2.3 ± 0.2) compared with cultures treated with Scr siRNA and noscapine (6.2 ± 0.9). By immunofluorescence microscopy, knockdown of AIF in cells decreased the punctate staining of AIF in the mitochondria and prevented its translocation to the nucleus with noscapine treatment. In contrast, cells transfected with Scr siRNA showed translocation of AIF to the nucleus when treated with noscapine.
Discussion
Here we have evaluated the sensitivity of four human glioma cell lines to noscapine-induced apoptosis. We found that the IC 50 values for the glioma cell lines ranged from 85 to 131 mmol/l, which differs from those reported for human lymphoid, melanoma, breast, and colon cell lines, most likely owing to differences in the cell types studied and their genetic alterations [14, 16, 19, 37, 43] . Similar to other microtubule binding agents, noscapine arrests cells in M-phase and alters the expression levels of cell cycle regulated proteins, such as increased expression of cyclin B1 and survivin and decreased levels of phospho-Cdc2, changes consistent with cells undergoing cell death by mitotic catastrophe [44, 45] .
Noscapine has been extensively analyzed for its mechanisms of action on microtubule dynamics and tubulin binding [8, 10, 13, 16, 18, 19, 37 ]. It appears to be unique among microtubule binding agents in that noscapine has subtle effects on microtubule steady-state dynamics. It neither promotes nor inhibits microtubule polymerization at concentrations of 100 mmol/l, but rather the microtubules spend an increased amount of time in a paused state, and as a result the total mass of tubulin remains unaltered [10] . This feature may explain its excellent toxicity profile demonstrated in both human and animal studies [8, 9, 15, 19, 20, 46] . The differential effects of microtubule binding agents on tumor cells, in general, have been attributed to the fact that tumor cells are deficient in the mitotic spindle assembly checkpoint, whereas normal cells are proficient [2, 4, 6] . Taken together, these findings underscore the potential importance of noscapine as an anticancer agent for use in a wide variety of cancers owing to its preferential toxicity for tumor cells compared with normal cells.
In contrast to activation of the JNK pathway by noscapine in glioma cells, we observed inactivation of the ERK signaling pathway associated with decreased levels of expression of phospho-ERK but no activation of p38 (data not shown). Inactivation of ERK signaling has been reported for KB-3 human epidermoid cells treated with vinblastine, vincristine, taxol, or colchicines [41] . However, treatment of MCF-7 breast cancer cells with some of the same drugs, including vincristine, taxol, or colchicine, did not change the activity of ERK [40] . Signaling events controlling apoptosis are complex and require a balance between growth promoting (ERK) and stress inducing (JNK) signals [47] . Our data would imply that induction of apoptosis in certain cell types, such as glioma and epidermal carcinoma, is associated with activation of JNK concomitant with inactivation of ERK signaling pathways. Of note, recent studies have correlated the induction of apoptosis with the inactivation of ERK and AIF translocation from the mitochondria [48, 49] .
Apoptosis induced by two noscapine analogs in CEM lymphoblastoid cell lines and drug-resistant sublines of ovarian carcinoma cell lines was associated with activation of caspase-3 and subsequent PARP cleavage [13, 18] . Most recently, noscapine-induced apoptosis in HL60 and K562 myeloid cells was associated with activation of several caspases and PARP cleavage [14] . In this study, we asked whether noscapine-induced cell death of glioma cells also occurred via a similar caspase-dependent pathway. The LN229 and T98G cell lines demonstrated the signature cleavage products of PARP within 24 h of noscapine treatment, whereas the U87MG and U118MG cell lines did not. When staurosporine was used in the same panel of cell lines, PARP cleavage was induced in all four glioma cell lines, indicating a caspase-dependent cell death. By western blotting and immunohistochemistry, we further confirmed that the presence of PARP cleavage was correlated with the cytochrome c release. In contrast, noscapine induced release of mitochondrial AIF in all cell 
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Noscapine induces release of cytochrome c to the cytosol and AIF translocation to the nucleus. The T98G (left column) and U87MG (right column) cell lines were untreated (a, b; e, f) or treated (c, d; g, h) with noscapine (100 mmol/l) for 16 h before immunohistochemistry for cytochrome c and AIF. Cells were fixed, permeabilized, and immunostained with anti-cytochrome c or anti-AIF antibody (green fluorescence) with counterstaining with PI (red fluorescence) to visualize nuclei. In T98G cells that undergo caspase-dependent apoptosis, noscapinetreated cells showed an increase in diffuse staining of cytochrome c in the cytoplasm (c) whereas in U87MG cells that undergo caspase-independent apoptosis, the cytocrome c staining in the cytoplasm remained punctate and associated with mitochondria (d). In contrast, in noscapine-treated T98G (g) and U87MG (h) cells, AIF translocated to the nucleus compared with untreated cells that retained the punctate cytosolic staining pattern of mitochondria (e, f). Yellow/ orange nuclear pattern indicates colocalization of the AIF and PI staining. By flow cytometry, AIF release from mitochondria and translocation to the nucleus is shown for T98G (i) and U87MG (j) cell lines. Cells were stained and fluorescence quantified on a LSRII flow cytometer. Representative histograms of the fluorescence intensity of the nuclear fractions from untreated (red line) and noscapine-treated (green line) cells are shown from one of two independent experiments. Noscapine treatment induced a two-fold increase in nuclear AIF fluorescence accumulation. AIF, apoptosis-inducing factor; FITC, fluorescein isothiocyanate; Nos, noscapine; PI, propidium iodide.
lines. To determine whether AIF played a role in cell death induced by noscapine treatment, we transfected U87MG cells with siRNA directed against AIF. Cell death in U87MG cells with knock-down of AIF expression was decreased compared with cells transfected with the Scr siRNA sequence. We have previously documented AIF release and caspase-independent apoptosis in flavopiridol-treated glioma cells [21] , whereas mitotic catastrophe induced in glioma cells treated with geldanamycin was associated with the release of both cytochrome c and AIF [23] . Others have reported caspase-dependent as well as caspase-independent cell death in breast cancer cells treated with doxorubicin [50] , caspase-dependent cell death in glioma cells treated with the novel cytokine melanoma differentiation associated gene-7/interleukin-24 [51] , or caspaseindependent but AIF-dependent cell death in glioma cells treated with a phosphoinositide-dependent kinase inhibitor OSU-03012 [52] , similar to what we have observed here.
To our knowledge, there has only been one previous report showing induction of Bcl-2 phosphorylation by noscapine [14, 43] , despite the fact that Bcl-2 phosphorylation is considered one of the hallmark responses to microtubule binding agents [2, 3] . Cells treated with microtubule binding agents induce the stress response kinase JNK that is responsible for the phosphorylation of Bcl-2 [2] [3] [4] 53, 54] . Normally, Bcl-2 functions as an inhibitor of apoptosis. However, its antiapoptotic activity can be inactivated by phosphorylation of specific residues in an unstructured loop of Bcl-2 [53] . Deletion of this loop region of Bcl-2 completely prevents apoptosis induced by the microtubule binding agent paclitaxel. The apoptosis signal-regulating kinase-1 phosphorylates Bcl-2 at the G 2 /M phase in normal cells as well as in cells exposed to paclitaxel [54] . Phosphorylated Bcl-2 binds with less affinity to Bax and other BH3-only proteins like Bim affecting the control of calcium release and overall apoptotic activity. Thus, this posttranslational modification of Bcl-2 affecting its binding to Bax may alter a critical ratio of these proteins that play pivotal roles in apoptosis [55, 56] . Our data suggest that noscapine may be capable of tipping the balance in favor of cell death through a combination of effects on mitochondria and survival signaling pathways. The fact that noscapine has been shown to cross the blood-brain barrier and demonstrate antitumor efficacy in the complete absence of peripheral neuropathy [17] , taken together with our in-vitro findings reported here, underscores the potential Noscapine induces AIF-dependent cell death. U87MG cells were transfected with scrambled (Scr) siRNA or siRNA directed to AIF. After 48 h, cells were treated with noscapine (100 mmol/l) for 16 h, and harvested for (a) western blotting with anti-AIF antibody and (b) trypan blue exclusion assay done in triplicate. The results of a representative experiment are shown from one of two independent experiments. (c) In a separate experiment, transfected U87MG cells were treated with noscapine (100 mmol/l) for 16 h before immunohistochemistry for AIF as described in the legend of Fig. 6 . Cells were immunostained with anti-AIF antibody (green fluorescence) and counterstained with propidium iodide (red fluorescence) to visualize nuclear morphology. The siRNA molecules are tagged with Alexa 488 and appear as bright blue dots in transfected cells. Noscapine induced AIF translocation to the nucleus in cells transfected with Scr siRNA compared with rare cells with nuclear AIF localization in cells transfected with siRNA directed to AIF. AIF, apoptosis-inducing factor; Nos, noscapine; siRNA, small interfering RNA. Newcomb et al. 561 importance of noscapine as a novel agent for use in patients with glioblastoma owing to its low toxicity profile and its potent anticancer activity.
Noscapine induces apoptosis
